<DOC>
	<DOC>NCT01342120</DOC>
	<brief_summary>The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone. The outcomes of interest are all-cause mortality, failed suicide attempts, extrapyramidal symptoms, diabetes mellitus, hypothyroidism, acute myocardial infarction and stroke. This retrospective cohort study is based on population-based record linkage system (PHARMO RLS) capturing about 2.5 millions residents in the Netherlands.</brief_summary>
	<brief_title>PHARMO Institute Seroquel Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Episode of new use of atypical antipsychotics in na√Øve (not used antipsychotic drugs for a year) users of antipsychotics. less than a year of recorded history before the cohort entry date use of multiple antipsychotics concomitantly duration and dose of the antipsychotic drug cannot be determined</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>atypical antipsychotics</keyword>
	<keyword>quetiapine</keyword>
</DOC>